Pluristem Therapeutics Company Profile (NASDAQ:PSTI)

About Pluristem Therapeutics

Pluristem Therapeutics logoPluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular, orthopedic, pulmonary, hematological and women's health diseases. The Company is focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient's own body. PLX cells are grown using its three-dimensional (3D), micro environment technology, which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PSTI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.67
  • 50 Day Moving Average: $1.56
  • 200 Day Moving Average: $1.52
  • 52-Week Range: $0.71 - $2.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.39
  • P/E Growth: 0.00
  • Market Cap: $133.87M
  • Outstanding Shares: 80,161,000
  • Beta: 0.76
Additional Links:
Companies Related to Pluristem Therapeutics:

Analyst Ratings

Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.17 (149.50% upside)

Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
DateFirmActionRatingPrice TargetDetails
8/4/2016HC WainwrightReiterated RatingBuy$3.50View Rating Details
7/27/2016Maxim GroupReiterated RatingBuyView Rating Details
7/11/2016FBR & CoReiterated RatingBuyView Rating Details
8/14/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details
2/3/2015Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00View Rating Details
9/22/2014Oppenheimer Holdings Inc.Initiated CoverageOutperformView Rating Details
9/15/2014Jefferies GroupLower Price TargetHold$3.50 -> $3.00View Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/24/2014($0.13)($0.09)ViewN/AView Earnings Details
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details
9/11/2014($0.15)($0.09)ViewN/AView Earnings Details
5/22/2014($0.14)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)
Current Year EPS Consensus Estimate: $-0.30 EPS
Next Year EPS Consensus Estimate: $-0.31 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)


Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
DateHeadline logoCan Shares Of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Get To $6? - Investor Newswire (NASDAQ:PSTI) - August 30 at 6:50 PM
News IconZeroing Our Focus on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI) - August 30 at 6:50 PM logoPluristem Therapeutics : PSTI) Secures $8 Million EU Grant for Critical Limb Ischemia Study (NASDAQ:PSTI) - August 25 at 7:06 PM
News IconPenny Stock Under the Microscope: Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI) - August 25 at 12:03 PM
News IconLooking Closer at Stocks of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI) - August 24 at 6:43 PM
News IconPluristem advances its u. s. fda trial in hematologic indication – nasdaq. com moto x data recovery (NASDAQ:PSTI) - August 20 at 6:37 PM
News IconStock Moving Up in Trade: Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Post News (NASDAQ:PSTI) - August 18 at 7:08 PM
News IconA Closer Look at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI) - August 17 at 9:57 AM
News IconSmall Cap Update on: Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Duncan Research (NASDAQ:PSTI) - August 15 at 7:20 PM logoWill Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Hit $6 Price Target? - Investor Newswire (NASDAQ:PSTI) - August 15 at 7:20 PM logoWill Pluristem Therapeutics Inc. (PSTI) Succeed in CLI Where Sanofi SA (ADR) (SNY) Failed? - Insider Monkey (blog) (NASDAQ:PSTI) - August 12 at 10:08 AM logoPluristem Therapeutics (PSTI) Receives $8M Grant for Phase III Critical Limb Ischemia Study - (NASDAQ:PSTI) - August 11 at 7:28 PM logoPluristem receives US$8mln EU grant for limb threat trial (NASDAQ:PSTI) - August 9 at 7:13 PM logoPluristem’s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe’s Horizon 2020 Program (NASDAQ:PSTI) - August 9 at 10:09 AM logoPluristem to run simultaneous US/ Europe limb threat trials (NASDAQ:PSTI) - August 4 at 10:08 AM logoPluristem Therapeutics, Inc. is trading above its 50 day moving average : PSTI-US : August 4, 2016 (NASDAQ:PSTI) - August 4 at 10:08 AM
News IconHere’s A Look At Two Promising CLI Companies And Their Near Term Milestones – Pluristem Therapeutics Inc. (PSTI) Cesca Therapeutics Inc (KOOL) (NASDAQ:PSTI) - August 3 at 3:56 PM logoPluristem (PSTI) Receives Positive Feedback from FDA on Phase III Trial of PLX-PAD in CLI (NASDAQ:PSTI) - August 3 at 10:13 AM logoPluristem to run simultaneous US and European limb threat trials (NASDAQ:PSTI) - August 2 at 11:56 AM logoPluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia (NASDAQ:PSTI) - August 2 at 11:56 AM
News IconPluristem Therapeutics Inc. (NASDAQ:PSTI) Updates On U.S. FDA Study In Hematologic Indication - Journal Transcript (NASDAQ:PSTI) - July 27 at 9:59 AM
News IconPluristem Therapeutics Inc. (NASDAQ:PSTI) Stock Gathers Momentum On Positive Clinical Trials Results - Journal Transcript (NASDAQ:PSTI) - July 27 at 9:59 AM logoPluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture (NASDAQ:PSTI) - July 27 at 7:38 AM logo7:01 am Pluristem Therapeutics intends to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture (NASDAQ:PSTI) - July 27 at 7:01 AM
News IconPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorted Shares Decreased By 4.32% - Press Telegraph (NASDAQ:PSTI) - July 22 at 9:53 AM logoPluristem Therapeutics (PSTI) Announces Participation in Radiation Injury Treatment Network's Meeting - (NASDAQ:PSTI) - July 20 at 9:49 AM logoPluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID (NASDAQ:PSTI) - July 20 at 7:00 AM logoPluristem Therapeutics, Inc. – Value Analysis (NASDAQ:PSTI) : July 19, 2016 (NASDAQ:PSTI) - July 19 at 2:48 PM
News IconPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorts Decreased by 11.39% After Short Covering - Consumer Eagle (NASDAQ:PSTI) - July 18 at 7:03 PM
News IconPluristem Therapeutics, Inc. (NASDAQ:PSTI) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:PSTI) - July 18 at 7:03 PM logoIs $6 Price Target Attainable For Pluristem Therapeutics, Inc. (NASDAQ:PSTI)? - Investor Newswire (NASDAQ:PSTI) - July 18 at 7:03 PM logoNext Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI) - Fiscal Standard (NASDAQ:PSTI) - July 18 at 7:03 PM logoBroker Outlook For Pluristem Therapeutics, Inc. (PSTI) - Fiscal Standard (NASDAQ:PSTI) - July 16 at 10:14 AM
News IconCrowd Rating and Earnings Recap for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Telanagana Press (NASDAQ:PSTI) - July 15 at 12:07 PM
News IconPluristem Therapeutics Inc (NASDAQ:PSTI) Institutional Investor Sentiment Analysis - Consumer Eagle (NASDAQ:PSTI) - July 13 at 7:22 PM logoStrong Sell Calls For Pluristem Therapeutics, Inc. (NASDAQ:PSTI) At 0 - Investor Newswire (NASDAQ:PSTI) - July 13 at 9:52 AM logoOption Market: Pluristem Therapeutics Inc Risk Hits An Extreme High - CML News (NASDAQ:PSTI) - July 13 at 9:52 AM logoPluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : July 13, 2016 (NASDAQ:PSTI) - July 13 at 3:02 AM logoPluristem Advances its U.S. FDA Trial in Hematologic Indication (NASDAQ:PSTI) - July 11 at 11:37 AM logoPluristem Advances Phase I Study Of PLX-R18 Cells To Treat Insufficient Hematologic (NASDAQ:PSTI) - July 11 at 9:45 AM
News IconRisky Sectors Produce Market Gains: Biotech & Healthcare Lead Pluristem Therapeutics Inc. (NASDAQ:PSTI), OXIS ... - Traders350 (NASDAQ:PSTI) - July 9 at 6:21 PM logoPluristem Therapeutics Inc. : Jobs Growth Spurs Boon to Stocks on Thursday (NASDAQ:PSTI) - July 7 at 7:00 PM logoPluristem Therapeutics, Inc. (NASDAQ:PSTI) Expected to Reach Highs Of $6 - Investor Newswire (NASDAQ:PSTI) - July 6 at 7:13 PM
News IconCan Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:PSTI) - July 6 at 7:13 PM
News IconStock Rating Watch and Earnings Insight for Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Press Telegraph (NASDAQ:PSTI) - July 6 at 7:13 PM logoBroker Outlook For The Week Ahead Pluristem Therapeutics, Inc. (PSTI) - Fiscal Standard (NASDAQ:PSTI) - July 6 at 7:13 PM logoStonegate Capital Partners Initiates Coverage on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - July 5 at 9:00 AM
News IconPluristem Therapeutics Incorporated (NASDAQ:PSTI) Short Interest Decreased By 11.39% - Engelwood Daily (NASDAQ:PSTI) - July 2 at 9:41 AM
News IconPluristem Therapeutics, Inc. (NASDAQ:PSTI) Company Rating and Target Watch - Telanagana Press (NASDAQ:PSTI) - June 30 at 9:48 AM
News IconPluristem Therapeutics Incorporated (NASDAQ:PSTI) Shorts Decreased by 11.39% After Short Covering - Press Telegraph (NASDAQ:PSTI) - June 29 at 6:52 PM


Pluristem Therapeutics (NASDAQ:PSTI) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff